Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Golden, Daniel W ^a   Novak, Caroline J ^a   Minsky, Bruce D ^a   Liauw, Stanley L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CA 19 9 antigen; Chemotherapy; Pancreas cancer; Radiotherapy dosage

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; DOCETAXEL; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GEMCITABINE; IRINOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; RADIATION DOSE; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; CARCINOMA; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLUOROURACIL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METALLOPORPHYRINS; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866069285     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-156     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the national cancer database. J Am Coll Surg 1999, 189:1-7. 10.1016/S1072-7515(99)00075-7, 10401733.
3. Ben-Josef E, Lawrence TS. Chemoradiotherapy for unresectable pancreatic cancer. Int J Clin Oncol 2008, 13:121-126. 10.1007/s10147-007-0763-x, 18463955.
4. Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol 2010, 7:437-447. 10.1038/nrgastro.2010.98, 20628346.
5. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813. 10.1200/JCO.2008.17.7188, 2668706, 19273710.
6. Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas 1995, 11:345-349. 10.1097/00006676-199511000-00005, 8532650.
7. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331. 10.1200/JCO.2006.07.5663, 17235048.
8. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755. Gastrointestinal Tumor Study Group.
9. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011, 29:4105-4112. 10.1200/JCO.2011.34.8904, 21969502.
10. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010, 8:972-1017. 3135380, 20876541.
11. Yoo T, Lee WJ, Woo SM, Kim TH, Han SS, Park SJ, Moon SH, Shin KH, Kim SS, Hong EK, et al. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2011, 81:e623-e630. 10.1016/j.ijrobp.2011.02.063, 21600705.
12. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4, 7284971.
13. Crane CH, Beddar AS, Evans DB. The role of intraoperative radiotherapy in pancreatic cancer. Surg Oncol Clin N Am 2003, 12:965-977. 10.1016/S1055-3207(03)00090-5, 14989127.
14. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004, 59:445-453. 10.1016/j.ijrobp.2003.11.003, 15145161.
15. Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, Article in press.
16. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320-323. 10.1016/j.ijrobp.2005.07.002, 16168826.
17. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009, 115:665-672. 10.1002/cncr.24059, 19117351.
18. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76:48-53. 10.1016/j.radonc.2004.12.022, 15990186.
19. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678-686. 10.1016/j.ijrobp.2008.01.051, 18395362.
20. Goyal K, Einstein D, Ibarra RA, Yao M, Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. J Surg Res 2012, 174:319-325. 10.1016/j.jss.2011.07.044, 21937061.
21. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 2011, 81:e615-e622. 10.1016/j.ijrobp.2011.04.045, 21658854.
22. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:809-816. 10.1016/j.ijrobp.2007.01.005, 17363191.
23. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55. 10.1002/cncr.22735, 17538975.
24. Slim N, Passoni P, Cattaneo M, Cereda S, Reni M, Longobardi B, Landoni C, Bettinardi V, Alongi F, Di Muzio N. Hypofractionated image-guided tomotherapy concomitant to capecitabine in advanced pancreatic adenocarcinoma. Preliminary results of a phase II study. Int J Radiat Oncol Biol Phys 2010, 78:S194.
25. Wakatsuki T, Irisawa A, Terashima M, Shibukawa G, Takagi T, Imamura H, Takahashi Y, Sato A, Sato M, Ikeda T, et al. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. Int J Clin Oncol 2011, 16:387-394. 10.1007/s10147-011-0197-3, 21331767.
26. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011, 18:619-627. 10.1245/s10434-010-1456-7, 21213060.
27. Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998, 41:393-396. 10.1016/S0360-3016(98)00058-3, 9607356.
28. Micke O, Bruns F, Kurowski R, Horst E, DeVries AF, Hausler JW, Willich N, Schafer U. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003, 57:90-97. 10.1016/S0360-3016(03)00524-8, 12909220.
29. Turrini O, Schmidt CM, Moreno J, Parikh P, Matos JM, House MG, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?. J Gastrointest Surg 2009, 13:1791-1797. 10.1007/s11605-009-0916-5, 19459018.